¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"oncogene proteins, viral"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® serum proteins ÇÑ±Û Ç÷û´Ü¹é
¼³¸í   
  Ç÷û¿¡ Àִ ´Ü¹éÁúµéÀ» ÃÑĪÇϴ ¸»·Î, ¸é¿ª±Û·ÎºÒ¸°(¸é¿ªÇö»ó¿¡ °ü¿©Çϴ Ç×ü¸¦ Çü¼ºÇÔ), ¾ËºÎ¹Î, º¸Ã¼ ¹× ÀÀ°íÀÎÀÚ¿Í ¿©·¯ È¿¼ÒµéÀÌ ÀÌ¿¡ ¼ÓÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cellular oncogene
    ¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ
  • signaling oncogene
    ½ÅÈ£Á¾¾çÀ¯ÀüÀÚ
  • arthropod-borne viral disease
    ÀýÁöµ¿¹°¸Å°³¹ÙÀÌ·¯½ºº´
  • viral
    ¹ÙÀÌ·¯½º-
  • viral capsid
    ¹ÙÀÌ·¯½ºÄ¸½Ãµå
  • viral conjunctivitis
    ¹ÙÀÌ·¯½º°á¸·¿°
  • viral disease
    ¹ÙÀÌ·¯½ºº´
  • viral dysentery
    ¹ÙÀÌ·¯½ºÀÌÁú
  • viral hemagglutination
    ¹ÙÀÌ·¯½ºÀûÇ÷±¸ÀÀÁý
  • viral hepatitis
    ¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type A
    AÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type B
    BÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type D
    DÇü¹ÙÀÌ·¯½º°£¿°
  • viral inclusion
    ¹ÙÀÌ·¯½ºÆ÷ÇÔ¹°
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ
  • viral conjunctivitis
    ¹ÙÀÌ·¯½º°á¸·¿°
  • viral hepatitis
    ¹ÙÀÌ·¯½º°£¿°
  • viral
    ¹ÙÀÌ·¯½º-
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cellular oncogene
    ¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ, Á¾¾ç¿ø
  • signaling oncogene
    ½ÅÈ£Á¾¾çÀ¯ÀüÀÚ
  • arthropod-borne viral disease
    ÀýÁöµ¿¹°¸Å°³¹ÙÀÌ·¯½ºº´
  • viral capsid
    ¹ÙÀÌ·¯½ºÄ¸½Ãµå
  • epidermal-epithelial viral disease
    Ç¥ÇÇ»óÇǹÙÀÌ·¯½ºº´
  • viral disease
    ¹ÙÀÌ·¯½ºº´
  • viral dysentery
    ¹ÙÀÌ·¯½ºÀÌÁú
  • viral hemagglutination
    ¹ÙÀÌ·¯½ºÀûÇ÷±¸ÀÀÁý
  • viral hepatitis
    ¹ÙÀÌ·¯½º°£¿°
  • viral inclusion
    ¹ÙÀÌ·¯½ºÆ÷ÇÔ¹°
  • viral particle
    ¹ÙÀÌ·¯½ºÀÔÀÚ
  • viral pneumonia
    ¹ÙÀÌ·¯½ºÆó·Å
  • viral
    ¹ÙÀÌ·¯½º-
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • G-proteins
    G-´Ü¹é(Ó±ÛÜ)
  • g proteins
    G ´Ü¹é
  • g-proteins
    G´Ü¹éÁú
  • guanosine triphosphate(gtp)-bindting proteins
    »ïÀλ걸¾Æ³ë½Å°áÇմܹéÁú
  • Erb-A oncogene
    Erb-A ¾ÏÀ¯ÀüÀÚ
  • Erb-B oncogene
    Erb-B ¾ÏÀ¯ÀüÀÚ
  • Fins oncogene
    Fins ¾ÏÀ¯ÀüÀÚ
  • proto-oncogene
    ¿øÁ¾¾çÀ¯ÀüÀÚ
  • proto-oncogene
    ¿øÇü¾ÏÀ¯ÀüÀÚ, ¿øÇü¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • proto-oncogene
    ¿ø¹ß¾ÏÀ¯ÀüÀÚ(ê«Û¡äßëºîîí­)
  • acute infectious gastroenteritis =epidemic viral
    ±Þ¼ºÀü¿°¼ºÀ§Àå¿°(¡­îîæøêÖíóæú).
  • acute infectious gastroenteritis =epidermic viral g.
    ±Þ¼º Àü¿°¼º À§Àå¿°(¡­îîæøàõêÖ æú).
  • acute viral hepatitis
    ±Þ¼º ¹ÙÀÌ·¯½º°£¿°(¡­ÊÜæú).
  • acute viral hepatitis
    ±Þ¼º¹ÙÀÌ·¯½º¼º °£¿° (~ÊÜæú)
  • arthropod-borne viral disease
    ÀýÁöµ¿¹° ¸Å°³ ¹ÙÀÌ·¯½ºº´
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • g proteins
    G ´Ü¹é
  • g-proteins
    G´Ü¹éÁú
  • glycosyl phosphatidyl inositol-linked proteins
    Glycosyl phosphatidyl inositol-linked proteins
  • guanosine triphosphate(gtp)-bindting proteins
    »ïÀλ걸¾Æ³ë½Å°áÇմܹéÁú
  • stress proteins
    ½ºÆ®·¹½º´Ü¹éÁú(¡­Ó±ÛÜòõ)
  • cellular oncogene
    ¼¼Æ÷¾ÏÀ¯ÀüÀÚ
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ(ðþåËë¶îîí­), Á¾¾ç¿ø(ðþåË¿ø)
  • proto-oncogene
    ¿øÇü¾ÏÀ¯ÀüÀÚ, ¿øÇü¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • proto-oncogene
    ¿øÁ¾¾çÀ¯ÀüÀÚ
  • proto-oncogene
    ¿ø¹ß¾ÏÀ¯ÀüÀÚ(ê«Û¡äßëºîîí­)
  • trk proto-oncogene
    trk¿øÇüÁ¾¾çÀ¯ÀüÀÚ
  • acute infectious gastroenteritis =epidemic viral
    ±Þ¼ºÀü¿°¼ºÀ§Àå¿°(¡­îîæøêÖíóæú).
  • acute infectious gastroenteritis =epidermic viral g.
    ±Þ¼º Àü¿°¼º À§Àå¿°(¡­îîæøàõêÖ æú).
  • acute viral hepatitis
    ±Þ¼º¹ÙÀÌ·¯½º¼º °£¿° (~ÊÜæú)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cellular oncogene
    ¼¼Æ÷ ¾ÏÀ¯ÀüÀÚ(á¬øàäßë¶îîí­)
  • oncogene
    ¾ÏÀ¯ÀüÀÚ(äßë¶îîí­)
  • oncogene theory
    ¾ÏÀ¯ÀüÀÚÀÌ·Ð(äßë¶îîí­ìµÖå)
  • viral coat
    ¹ÙÀÌ·¯½º ¿ÜÇÇ(èâù«)
  • viral hepatitis
    ¹ÙÀÌ·¯½º¼º °£¿° (ÊÜæú)
  • viral interference
    ¹ÙÀÌ·¯½º °£¼·(ÊÎàï)
  • viral yield
    ¹ÙÀÌ·¯½º ¼öÀ²(â¥ëÒ)
  • bundling proteins
    ±Ù¼Ó´Ü¹éÁú(ÐÉáÖÓ±ÛÜòõ)
  • capping proteins
    ĸÇü¼º(û¡à÷) ´Ü¹éÁú(Ó±ÛÜòõ)
  • extrinsic proteins
    ¿ÜÀÎ ´Ü¹éÁú (èâì×Ó±ÛÜòõ)
  • high-quality proteins
    °í±Þ ´Ü¹éÁú(ÍÔÐäÓ±ÛÜòõ)
  • integral proteins
    ÅëÇմܹéÁú(÷ÖùêÓ±ÛÜòõ)
  • labile proteins
    ºÒ¾ÈÁ¤´Ü¹éÁú(ÝÕäÌïÒÓ±ÛÜòõ)
  • microtubule-associated proteins
    ¹Ì¼Ò°ü ¿¬°ü´Ü¹éÁú(Ú°á³Î·æáμӱÛÜòõ)
  • nonbasic chromosomal proteins
    ºñ¿°±â¼º ¿°»öü´Ü¹éÁú(Þªç¤Ðñàõæøßäô÷Ó±ÛÜòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • viral
    ¹ÙÀÌ·¯½º¼ºÀÇ
  • viral infection
    ¹ÙÀÌ·¯½º°¨¿°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
V-ONC viral oncogene
PBPs Penicillin-Binding Proteins
PVM pneumonia virus of mice; proteins, vitamins, and minerals
RPSP reference preparation for serum proteins
GnRH Gonadotropin Releasing Hormone  [HP 1898, 2034]
  = LHRH
  = Go...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
G proteins GIP-binding proteins
G-proteins GTP)-binding regulatory proteins
G-proteins Guanine nucleotide-binding regulatory proteins
G proteins reglatory proteins
c-onc cellular oncogene
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cellular oncogene
    ¼¼Æ÷ ¾Ï À¯ÀüÀÚ
    ¼¼Æ÷ÀÇ ¿øÀο¡ ÀÇÇØ¼­ Á¾¾çÇü¼ºÀ» ÀÏÀ¸Å°´Â À¯ÀüÀÚ.
  • anti-viral agent
    Ç×¹ÙÀÌ·¯½ºÁ¦
    ¹ÙÀÌ·¯½º¸¦ º´¿øÃ¼·Î ÇÏ´Â Áúº´. Áï, Æ®¶óÄÚ¸¶¡¤¼Ò¾Æ¸¶ºñ
  • arthropod viral disease
    ¾Æ¸£º¸ ¹ÙÀÌ·¯½º Áúȯ, ÀýÁöµ¿¹° ¸Å°³ ¹ÙÀÌ·¯½º Áúȯ, ÀýÁöµ¿¹° ¸Å°³¼º ¹ÙÀÌ·¯½º Áúȯ
    µ¿ÀǾî=arbovirus disease.
  • arthropodborne viral fever
    ÀýÁöµ¿¹° ¸Å°³ÀÇ ¹ÙÀÌ·¯½º ¿­
  • chronic slow viral encephalitis
    ¸¸¼º Áö¿¬Çü ¹ÙÀÌ·¯½º¼º ³ú¿°
  • influenzal viral pneumonia
    ÀÎÇ÷翣ÀÚ Æó·Å
    ÀÎÇ÷翣ÀÚ¿¡ °É·Á ÀúÇ×·ÂÀÌ ÀúÇϵǾúÀ» ¶§ ±âµµ¿¡ ÀÖ´ø ¼¼±ÕÀÌ Áõ½ÄµÇ¾î ÀϾ´Â Æó·Å. ÀÌ¿Í °°ÀÌ 2Â÷ °¨¿°À» ÀÏÀ¸Å°´Â ¼¼±ÕÀº Æ÷µµ ±¸±Õ , Æó·Å ±¸±Õ , ¿¬¼â ±¸±Õ , ÀÎÇ÷翣ÀÚ ±Õ , Æó·Å °£±Õ µîÀÌ´Ù. º»ÁõÀÇ ÇÕº´·üÀº À¯Çà¿¡ µû¶ó Å« Â÷°¡ ÀÖÀ¸¸ç ¿¬·ÉÀûÀ¸·Î´Â ³ëÀÎÀÇ °æ¿ì¿¡ ³ô´Ù. Áõ¼¼´Â ÀÎÇ÷翣ÀÚÀÇ °í¿­ÀÌ 2¡­3ÀÏÀÌ µÇ¾îµµ ³»¸®Áö ¾Ê°í, ¶Ç´Â ÀÏ´Ü ³»·È´ø ¿­ÀÌ ´Ù½Ã »ó½ÂÇϸ鼭 È£Èí °ï¶õµµ ´õ¿í ½ÉÇØÁø´Ù. ÀÔ¼úÀ̳ª ¼Õ³¡Àº Â÷°¡¿öÁö°í ûÀÚ»öÀ» ¶í´Ù. ±âħ°ú ´ãµµ ¸¹À¸¸ç, ÈäºÎÀÇ Ã»Áø , ŸÁøÀ̳ª X¼± °Ë»ç¿¡¼­ Æó·ÅÀÇ ¼Ò°ßÀÌ Áõ¸íµÈ´Ù. Ä¡·á´Â 2Â÷ °¨¿°±Õ¿¡ ÀûÀÀµÇ´Â Ç×»ý ¹°ÁúÀ» ¾²´Â ¿Ü¿¡ ÀÏ¹Ý Æó·ÅÀÇ Ä¡·á¿¡ ÁØÇÑ´Ù. ³ëÀÎÀÇ °æ¿ì´Â »ç¸Á·üÀÌ ³ôÀ¸¸ç, ¶ÇÇÑ ÀÎÇ÷翣ÀÚ·Î »ç¸ÁÇÏ´Â »ç¶÷ÀÇ ¾à 80 %´Â Æó·ÅÀÇ ÇÕº´ ¶§¹®ÀÌ´Ù.
  • viral antibody
    ¹ÙÀÌ·¯½º Ç×ü
  • viral arthritis
    ¹ÙÀÌ·¯½º °üÀý¿°, ¹ÙÀÌ·¯½º¼º °üÀý¿°
  • viral capsid antigen
    ¹ÙÀÌ·¯½º ĸ½Ãµå Ç׿ø, ¹ÙÀÌ·¯½º¼º ĸ½Ãµå Ç׿ø
  • viral demonstration
    ¹ÙÀÌ·¯½º Áõ¸í
  • viral diarrhea
    ¹ÙÀÌ·¯½º ¼³»ç, ¹ÙÀÌ·¯½º¼º ¼³»ç
  • viral dysentery
    ¹ÙÀÌ·¯½º ÀÌÁú, ¹ÙÀÌ·¯¼º ÀÌÁú
  • viral encephalitis
    ¹ÙÀÌ·¯½º ³ú¿°, ¹ÙÀÌ·¯½º¼º ³ú¿°
    ¹ÙÀÌ·¯½º °¨¿°À¸·Î ³ú¿¡ ¿°ÁõÀÌ ¹ß»ýÇÏ´Â °Í. ¼ö¸·¿°À» ¼ö¹ÝÇÏ¿© ô¼ö¿¡ ÆÄ±ÞµÈ´Ù.
  • viral gastroenteritis
    ¹ÙÀÌ·¯½º À§Àå¿°, ¹ÙÀÌ·¯½º¼º À§Àå¿°
  • viral hemagglutination
    ¹ÙÀÌ·¯½º Ç÷±¸ ÀÀÁý¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
oncogene proteins, viral Products of viral oncogenes, most commonly retroviral oncogenes. They usually have transforming and often protein kinase activities.
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
viral oncogene <molecular biology> A viral gene that contributes to cancer development in vertebrate hosts.
(09 Oct 1997)
proto-oncogene proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
(12 Dec 1998)
proto-oncogene proteins c-abl Membrane proteins encoded by the c-abl genes. They exhibit tyrosine kinase activity and play a role in normal haematopoiesis especially of the myeloid lineage. Oncogenic transformation of c-abl arises when specific n-terminal amino acids are deleted, releasing the kinase from negative regulation.
(12 Dec 1998)
proto-oncogene proteins c-bcl-2 Membrane proteins encoded by the bcl-2 genes and serving as a potent inhibitor of cell death by apoptosis. The proteins are found on mitochondrial, microsomal, and nuclear membrane sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
(12 Dec 1998)
proto-oncogene proteins c-erbb-2 Cellular proteins in the epidermal growth factor receptor family encoded by the c-erbb genes. These proteins are overexpressed in a significant portion of adenocarcinomas found at various sites, especially in the breast. Gene amplification appears to be the predominant method leading to overexpression.
(12 Dec 1998)
proto-oncogene proteins c-fos Cellular DNA-binding proteins encoded by the c-fos genes (genes, fos). They are involved in growth-related transcriptional control. C-fos combines with c-jun (proto-oncogene proteins c-jun) to form a c-fos/c-jun heterodimer (transcription factor ap-1) that binds to the tre (tpa-responsive element) in promoters of certain genes.
(12 Dec 1998)
proto-oncogene proteins c-jun Cellular DNA-binding proteins encoded by the c-jun genes (genes, jun). They are involved in growth-related transcriptional control. There appear to be three distinct functions: dimerization (with c-fos), DNA-binding, and transcriptional activation. Oncogenic transformation can take place by constitutive expression of c-jun.
(12 Dec 1998)
proto-oncogene proteins c-kit Tyrosine kinase membrane receptors which are the natural ligands for mast cell growth factor (steel factor). This interaction is crucial for the development of haematopoietic, gonadal, and pigment stem cells.
(12 Dec 1998)
proto-oncogene proteins c-met <enzyme> A transmembrane tyrosine kinase that is the receptor for hepatocyte growth factor (scatter factor). It consists of an extracellular alpha chain which is disulfide linked to the transmembrane beta chain. The cytoplasmic portion contains the catalytic domain and critical sites for the regulation of kinase activity.
Registry number: EC 2.7.11.-
(12 Dec 1998)
proto-oncogene proteins c-mos Cellular proteins encoded by the c-mos genes (genes, mos). They function in the cell cycle to maintain maturation-promoting factor in the active state and have protein-serine/threonine kinase activity. Oncogenic transformation can take place when c-mos proteins are expressed at the wrong time.
(12 Dec 1998)
proto-oncogene proteins c-myc Cellular DNA-binding proteins encoded by the c-myc genes. They are normally involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Elevated and deregulated (constitutive) expression of c-myc proteins can cause tumourigenesis.
(12 Dec 1998)
proto-oncogene proteins c-raf <enzyme> A class of serine-threonine kinases involved in cellular signal transduction. Included in this class are the proto-oncogene proteins mil and raf. Raf is a component of a signal transduction pathway leading to increased gene expression through the c-jun DNA binding site, ap1.
Registry number: EC 2.7.10.-
(12 Dec 1998)
oncogene proteins Proteins coded by oncogenes. They include proteins resulting from the fusion of an oncogene and another gene (oncogene proteins, fusion).
(12 Dec 1998)
oncogene proteins, fusion The translation products of the fusion between an oncogene and another gene. The latter may be of viral or cellular origin.
(12 Dec 1998)
oncogene proteins v-abl Transforming proteins encoded by the abl oncogenes. Oncogenic transformation of c-abl to v-abl occurs by insertional activation that results in deletions of specific n-terminal amino acids.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Oncogene Proteins, Viral - »õâ Products of viral oncogenes, most commonly retroviral oncogenes. They usually have transforming and often protein kinase activities.
    Synonyms : Transforming Proteins, Viral, v onc Proteins
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • oncogene
    ¹ß¾ÏÀ¯ÀüÀÚ
  • viral
    ¹ÙÀÌ·¯½ºÀÇ;¿©°ú¼º º´¿øÃ¼ÀÇ;¹ÙÀÌ·¯½º¼ºÀÇ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á